Skip to main content
Toggle navigation
Login
Search
Home
Conference Program
Icon Legend
This session is not in your schedule.
This session is in your schedule. Click again to remove it.
Home
Browse by Poster Presenter
Browse by Poster Presenter
Type here to filter the list
All
A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z
D
Dalton, Mackenzie
Clarkson University
(
M-023
)
Evaluating the Importance of Glucagon in the Insulin-Glucose Regulatory System: A Mechanistic Modeling Approach
Mackenzie Dalton
Favorite
Davenport, Angelica
Genmab
(
T-030
)
Integration of Temporal Single-Cell RNA Sequencing Data into Quantitative Systems Pharmacology Model of T Cell Differentiation
Angelica Davenport
Favorite
D'Cunha, Ronilda
AbbVie
(
M-075
)
Leveraging Digital Biomarkers to Enhance Clinical Pharmacology and Pharmacometrics Informed Drug Development: A Case Study
Ronilda D'Cunha
Favorite
de Jong, Jan
Immuneering Corporation
(
W-019
)
Phase 1 Interim Population Pharmacokinetic/Pharmacodynamic Model and Phase 2 Dose Exploration for IMM-1-104, a Novel Concept Oral Deep Cyclic MEK Inhibitor.
Jan de Jong
Favorite
De Witte, Wilhelmus
ESQlabs
(
W-020
)
In-depth numerical model analysis tools to gain insight into model behavior of large-scale pharmacometric models
Wilhelmus De Witte
Favorite
(
W-021
)
Local TMDD of large molecules in tissue interstitial space
Wilhelmus De Witte
Favorite
Debroy, Swati
Certara
(
W-022
)
Simulations to Inform Dose Selection for a Phase 2b Trial Investigating TOUR006, a Fully Human Anti-IL6 Antibody, for Treatment of Thyroid Eye Disease
Swati Debroy
Favorite
Dela, An
Simulations Plus
(
T-031
)
Comparison of Sensitivity Analysis Methods in the Context of a QSP Model for Gout
An Dela
Favorite
Delff, Philip
Vertex Pharmaceuticals
(
T-032
)
NMsim: Simulate Nonmem models seamlessly in R without any model reimplementation
Philip Delff
Favorite
Demin Jr, Oleg
InSysBio CY
(
M-024
)
Mechanistic Translational Modeling Versus Minimal Anticipated Biological Effect Level Approach to Predict First-in-human Dose For T-cell Engagers: HPN536 Case Study.
Oleg Demin Jr
Favorite
(
T-047
)
FIVEDB as a tool for analysis of in vitro experimental data: cytokine production by primary cells and cell lines
Oleg Demin Jr
Favorite
(
W-060
)
Quantitative systems pharmacology model for distinguishing efficacy of anti-CD20 therapy variants in populations of Multiple Sclerosis patients
Oleg Demin Jr
Favorite
(
W-061
)
Quantitative systems pharmacology modeling of neurotoxicity and cognitive scores in Alzheimer’s disease for prediction of therapy outcomes
Oleg Demin Jr
Favorite
Denney, William S
Human Predictions
(
W-023
)
Optimized Noncompartmental Half-Life Estimation with Tobit Regression
William S Denney
Favorite
Desai, Devam
Center of Pharmacometrics and Systems Pharmacology, University of Florida, Orlando, FL
(
T-033
)
A translational one pore and two pore whole body physiologically based pharmacokinetic model for ASOs, and siRNA-based therapeutics
Devam Desai
Favorite
Dhakal, Saroj
Sanofi
(
W-024
)
Small molecule exposure prediction (intravenous (IV) and oral (PO)) using Machine learning (ML) in combination with mechanistic modeling.
Saroj Dhakal
Favorite
DiBartolo, Sarah
(
M-025
)
A quantitative systems pharmacology (QSP) model to enable prediction of ARIA-E incidence with anti-Aβ monoclonal antibody therapies for Alzheimer’s disease
Sarah DiBartolo
Favorite
Djebli, Nassim
Luzsana Biotechnology
(
W-049
)
Exposure-Response Analysis for Hepatotoxicity of Rivoceranib Monotherapy and in Combination with Camrelizumab in Patients with Various Cancers, Including Advanced Hepatocellular Carcinoma
Nassim Djebli
Favorite
Dodds, Michael
Certara USA, Inc
(
M-026
)
Augmented Definitive Screening Design Provides Efficient Phase 1 Selection of CAR T-cell and Lymphodepletion Regimen
Michael Dodds
Favorite
Dogra, Prashant
Houston Methodist Research Institute
(
T-034
)
Translational modeling identifies synergistic combinations of anti-microRNA-155 with standard-of-care drugs in non-small-cell lung cancer
Prashant Dogra
Favorite
(
T-035
)
Identifying Determinants of Vaccine Efficacy: A Mechanistic Modeling Approach
Prashant Dogra
Favorite
Doi, Yohei
Faculty of Pharmaceutical Sciences, Kyushu Univercity, Fukuoka, Japan
(
M-027
)
Model-based meta-analysis of safety for monomethyl auristatin E-conjugated antibody drug conjugates in cancer patients
Yohei Doi
Favorite
Dombrowsky, Erin
Bristol Myers Squibb
(
M-028
)
A systematic approach for imputing missing dose information in population pharmacokinetic analysis datasets
Erin Dombrowsky
Favorite
Dong, Jin
AstraZeneca
(
M-029
)
Bilirubin Elevation Due To Atazanavir Treatment May Primarily Be Mediated By Inhibition Of OATP1B1/3 Rather Than That Of UGT1A1: PBPK Analysis Of Bilirubin-Atazanavir-Polymorphism Interaction
Jin Dong
Favorite
Dotan, Or
Teva Pharmaceuticals, Ltd.
(
W-025
)
Population pharmacokinetic analysis of anti-interleukin-15 monoclonal antibody TEV-53408 in healthy volunteers
Or Dotan
Favorite
(
W-026
)
Population pharmacokinetic and pharmacodynamic analysis of natural killer cell levels in response to TEV-53408, an anti-interleukin 15 monoclonal antibody, in healthy volunteers
Or Dotan
Favorite
Drescher, Stefanie
Pfizer INC
(
W-027
)
Population Pharmacokinetic (PopPK) Model to Characterize Pharmacokinetics (PK) of Vepdegestrant, a Proteolysis Targeting Chimera (PROTAC) Estrogen Receptor (ER) Degrader, in Healthy Adult Participants
Stefanie Drescher
Favorite
Duffull, Stephen
Certara
(
M-031
)
Development and application of a mechanistic model for Alzheimer’s Disease
Stephen Duffull
Favorite
Du, Lihong
Merck & Co., Inc.,
(
M-030
)
A Minimal QSP Model for Treg Responses of IL-2 Mutein MK-6194 – A Conceptual Model for Autoimmune Disease
Lihong Du
Favorite
Duong, Khanh Linh
Chungnam National Univesity
(
W-028
)
Development and application of physiologically based pharmacokinetic model of darunavir on pregnant population
Khanh Linh Duong
Favorite
Du, Ruihu
Drug Clinical Trial Center, Peking University Third Hospital, Beijing, 100191, China
(
T-038
)
The PK-PD model of dexamethasone for fetal lung maturation and developmental neurotoxicity: A dose optimization study
Ruihu Du
Favorite
du, Shengnan
BMS
(
T-036
)
A Novel Empirical Drug Induced Autoinduction Model to Characterize the Population Pharmacokinetics of Repotrectinib with Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements
Shengnan du
Favorite
(
T-037
)
Exposure-Response Efficacy and Safety Analysis of Repotrectinib to Support the Dose Recommendation for Patients with ROS1-positive NSCLC
Shengnan du
Favorite
